In a study, 53.1% of patients had concomitant prostate cancer in radical cystectomy specimens.
ASS1 loss occurs in invasive bladder cancer and is targetable by ADI-PEG 20.
After analyzing new data, the FDA again warns that the diabetes drug may be associated with an increased risk for bladder cancer.
Before and after radical cystectomy, thromboembolic events are common in bladder cancer patients who undergo neoadjuvant chemotherapy.
Low levels of vitamin D in the blood may prevent the cells within the bladder from stimulating an adequate response to abnormal cells.
Predictors of distant recurrences after robot-assisted radical cystectomy were mainly dictated by pathological tumor characteristics.
Based on a small study, investigators report encouraging efficacy and safety.
Increased type I collagen mRNA expression in the extracellular matrix microenvironment is associated with poor progression-free survival.
Patients who underwent a radical cystectomy (RC) developed postoperative infection after a median of 13 days.
Patients with diabetes had a significant 42% increased risk of recurrence of cancer and 79% increased risk of progression.
This approach is associated with a 26% decreased risk of disease recurrence at 15 years compared with alternating therapy with mitomycin C.
Tumors in the dome or urachus confer a better prognosis than those in the lateral wall and base, study finds.
Assay could cut down on cystoscopies, researchers say.
Second cancer was fatal in 55% of the cases studied.
Diabetics taking the drug had a significant 68% decreased risk of grade progression compared with diabetics not on the drug.
Researchers find no difference in 5-year disease-specific survival between multi-disciplinary bladder-sparing approach and radical cystectomy.
During first 24 months, 8.7% of patients with favorable pathological characteristics had progressed.
Women with stage IV bladder cancer have a lower median overall survival rate when compared to men.
About a quarter of older patients deemed too frail for chemo responded to atezolizumab.
Four key lifestyle factors include weight, exercise, no smoking, and limiting alcohol.
Atezolizumab received accelerated FDA approval for patients whose disease has progressed despite platinum-based chemotherapy.
Findings for self-reported leisure-time physical activity of moderate to vigorous intensity.
In a meta-analysis, men with benign prostatic hyperplasia had a 2.9 times and 1.7 times increased incidence of prostate cancer and bladder cancer, respectively.
Bladder cancer risk increases with longer duration of use.
Researchers found elevated incidences of upper tract urothelial carcinoma (UTUC) in patients with CKD.
Patients who underwent debulking had significantly longer overall survival compared with those who did not (median 15.7 vs 10 months).
Therapy used in less than 5% of cases, even in those with higher clinical stage.
Mortality risk decreases with increasingly stringent BPT compared with radical cystectomy.
African American survivors had lower intakes of 8 select micronutrients, such as folate, compared with Caucasian survivors.
The increased risk occurs more than 10 years after treatment and most pronounced in men who undergo brachytherapy.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)